Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is showing promising outcomes in initial clinical trials . Current research https://myfirstbookmark.com/story21390153/retatrutide-emerging-studies-and-possible-therapeutic-roles